161 CLINICAL CONSEQUENCES OF OFF-LABEL REDUCED DOSING OF NOACS IN AF Other 9 FDA Other 8 J-ROCKET-AF FDA FDA SPC ARISTOTLE + SPC + other 7 ARISTOTLE + other 6 ESC ROCKET-AF Other 5 ARISTOTLE + other 4 ARISTOTLE Other 3 J-ROCKET-AF SPC ARISTOTLE ROCKET-AF R: ROCKET-AF; A: ARISTOTLE Other 2 FDA D: FDA; R: other 2 J-ROCKET-AF SPC Guideline used 3,340 5,399 4,653 661 707 7,925 27,765 2,195 1,658 8,512 13,594 844 1,245 6,294 6,443 6,521 10 13,092 6,929 9,639 16,568 19,712 8,035 27,747 6,806 8,425 NOAC users (n) 4.0 ǂ 4.0 ǂ 4.0 ǂ 10.8 ǂ 16.3 12.0 ǂ 15.3 13.4 39.3 ǂ 24 ǂ 16.8 ǂ ±12 13.4 17.4 15.1 ǂ ±12 11.6 ǂ 15.0 ǂ 15.0 ǂ 15.0 ǂ 11.6 14.8 12.5 n.r. 23 Duration of follow-up (months) Patient characteristics 50.6 59.9 61.7 78 48.7 58.7 48.3 63.6 71.5 56 57.4 62.2 73.6 58.9 66.9 68.3 56.8 47.4 59.4 54.4 50.2 50.6 50.3 67.7 48.0 Male sex (%) 72.4 69.6 68.3 69.1 75.1 71 ǂ 78.7 71.6 71.7 72.6 69.8 ǂ 74.0 67.2 74.5 70.9 70.4 73.6 71.0 69.8 70.3 n.r. n.r. n.r. 71.6 75.5 Age in years (mean) n.r. n.r. n.r. 67.1 86.9 n.r. 78.1 60.9 63.8 63.6 64.9 n.r. 65.8 59.5 62.7 64.9 81.0 n.r. n.r. n.r. n.r. n.r. n.r. 62.7 n.r. Weight in kg (mean) n.r. n.r. n.r. n.r. n.r. n.r. n.r. 23.7 24.1 24.6 24.8 n.r. n.r. n.r. 24.0 24.7 28.1 25.0 25.5 25.3 n.r. n.r. n.r. n.r. 30.2 Body mass index (mean) 8
RkJQdWJsaXNoZXIy MTk4NDMw